On the Record · Hims & Hers Health
Hims & Hers Health acquisitions, on the record
The businesses Hims & Hers Health bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
YoDerm, Inc. ("Apostrophe")Word for word“In July 2021, we completed our acquisition of YoDerm, Inc. (“Apostrophe”), allowing us to expand personalized dermatological offerings to our customers.” 10-K for 2023 | acquisition | July 2021 | — |
Honest Health Limited (now Hims & Hers UK Limited, "HHL")Word for word“We expanded into the United Kingdom in early 2021, and in June 2021, we completed our acquisition of U.K.-based Honest Health Limited, which is now Hims & Hers UK Limited (“HHL”), a company that offers health and wellness products and services.” 10-K for 2023 | acquisition | June 2021 | — |
Seaview Enterprises, LLC (d/b/a MedisourceRx) ("MedisourceRx")Word for word“In 2024, we acquired Seaview Enterprises, LLC (d/b/a MedisourceRx) (“MedisourceRx”), a licensed 503B compounding outsourcing facility, which compounds products primarily for Hims & Hers customers (our “Outsourcing Facility”).” 10-K for 2024 | acquisition | In 2024 | — |
C S Bio, Co. peptide manufacturing facility and certain related assets ("Peptide Facility")Word for word“In February 2025, we satisfied all closing conditions of an asset purchase agreement, executed in December 2024, to acquire certain manufacturing assets from a company located in the United States , for total cash and Class A common stock consideration up to approximately $65.0 million.” 10-K for 2024 | agreed acquisition | February 2025 | approximately $65.0 million |
Sigmund NJ, LLC, marketed as Trybe Labs ("Lab Facility")Word for word“Also in February 2025, we acquired Sigmund NJ, LLC, marketed as Trybe Labs, a lab testing services business, which will allow us to add lab testing capabilities to our platform in the future (our “Lab Facility”).” 10-K for 2024 | acquisition | February 2025 | — |
Seaview Enterprises LLC (d/b/a MedisourceRx)Word for word“In September 2024, we satisfied all closing conditions of the executed purchase agreement to acquire all of the membership interests of Seaview Enterprises LLC (d/b/a MedisourceRx) (“MedisourceRx”), a 503B compounding outsourcing facility registered with the Food and Drug Administration and located in the United States , for total cash and stock consideration of approximately $31.0 million, including cash payments of $15.5 million and Class A common stock of $15.5 million.” 10-K for 2024 | acquisition | In September 2024 | approximately $31.0 million |
ZavaWord for word“For instance, in July 2025, we completed the acquisition of Zava, a digital health platform with operations in the United Kingdom, Germany, Republic of Ireland, France, and Spain, and in November 2025, we completed the acquisition of Medici, a digital health platform with operations in Canada.” 10-K for 2025 | acquisition | July 2025 | — |
MediciWord for word“For instance, in July 2025, we completed the acquisition of Zava, a digital health platform with operations in the United Kingdom, Germany, Republic of Ireland, France, and Spain, and in November 2025, we completed the acquisition of Medici, a digital health platform with operations in Canada.” 10-K for 2025 | acquisition | November 2025 | — |
EucalyptusWord for word“The aggregate total consideration of the transaction is up to $1.15 billion, subject to certain adjustments set forth in the Deed (the “Proposed Acquisition”).” 10-K for 2025 | agreed acquisition | — | up to $1.15 billion |
peptide manufacturing facility (and related assets)Word for word“Further, in February 2025, we acquired a peptide manufacturing facility (and related assets).” 10-K for 2025 | acquisition | February 2025 | — |
licensed 503B outsourcing facilityWord for word“In May 2024, we began offering access to GLP-1s as part of our weight loss offering, first in the form of compounded injectable semaglutide, and in September 2024, we acquired a licensed 503B outsourcing facility.” 10-K for 2025 | acquisition | September 2024 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2019-12-31 | $0 | — |
| 2020-12-31 | $0 | — |
| 2021-12-31 | $46.5 million | $110.9 million |
| 2022-12-31 | $0 | — |
| 2023-12-31 | $0 | — |
| 2024-12-31 | $15.4 million | $1.8 million |
| 2025-12-31 | $145.2 million | $165.3 million |
Deal filings since 2016
- 2026-07-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-06-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-05-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-02-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-09-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-05-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-01-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-01-26 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2020-10-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-07-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Hims & Hers Health’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-23. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.